AlphAIalphai — Financial news for AI agents
investing.comAUG 262 min read$SMMT

Why is Summit Therapeutics stock surging today?

Summit Therapeutics (SMMT) stock rose 8.5% in pre-market trading after positive clinical trial data for its drug ivonescimab. Partner Akeso reported success in a Phase III study for advanced biliary tract cancer, and Summit published results showing reduced disease progression risk in lung cancer. Analysts Guggenheim and Bernstein SocGen updated their ratings and price targets. The rally was company-specific, with the broader market showing little movement.

Original reporting
investing.com
Published Aug 26, 2026, 11:40 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 26, 2026, 11:43 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefMarket movers
Primary signal
$SMMT
Bullish
high confidence
Mentioned
$SMMT
Relevance
9/10
alphai data visualization · based on investing.com
Decision brief

The 30-second read

$SMMTBullishHigh
01

Why it matters

The dual positive trial readouts provide a rare, high‑impact catalyst for a small‑cap biotech, justifying the sharp pre‑market move.

02

Market read

The news creates immediate trading opportunity and may reshape valuation of similar oncology assets.

03

What to watch

Upcoming competitive data from other immunotherapy trials could temper long‑term upside.

Relevance 9/10Novelty 9/10Timing: pre‑market today

Background

Summit Therapeutics (SMMT) is a clinical‑stage biotech focused on immuno‑oncology.

Company-level read

Ticker impact

$SMMTBullishHigh confidence
Context

Summit Therapeutics stock jumped 8.5% pre‑market after positive Phase III trial data for ivonescimab in biliary tract cancer and a Lancet Oncology publication on lung cancer.

Expected impact

Further upside expected if FDA approval follows; watch for volatility ahead of November FDA decision.

Evidence & confidence

Phase III OS win and strong progression data are material catalysts for a biotech, historically driving multi‑digit moves.

Market effects

Sector

Biliary‑tract and lung‑cancer biotech sector may see renewed investor interest.

Regional

US biotech market gains modestly as the news is US‑listed.

Global

Potentially influences global oncology drug pipelines and competitor valuations.

Counterpoint

What could challenge this read

If the FDA delays or requests additional data, the rally could reverse quickly.

Key entities

  • company
    Summit Therapeutics

    Clinical‑stage biotech developing ivonescimab.

  • partner
    Akeso

    Co‑developer of ivonescimab, announced Phase III biliary tract cancer result.

Read at source← All news

Also covered by

1 outlet

Related articles

AUG 26
$SMMTHighAI 9/10

Summit Therapeutics stock jumps on partner’s cancer trial data

Summit Therapeutics (SMMT) shares rose 7.75% after its partner Akeso's Phase III cancer study met primary and key secondary endpoints. The study showed ivonescimab plus chemotherapy improved overall survival in advanced biliary tract cancer. Analysts had mixed reactions, with H.C. Wainwright maintaining a Neutral rating and Guggenheim reiterating a Buy with a $38 price target.

investing.com2 min
AUG 25
$SMMTMedAI 8/10

Summit's Ivonescimab+ Chemotherapy Shows Significant PFS Benefit In Phase III HARMONi Trial

Summit Therapeutics (SMMT) reported Phase III HARMONi trial results in The Lancet Oncology, showing ivonescimab plus chemotherapy improved progression-free survival (6.8 months vs. 4.4 months) in EGFR-mutated NSCLC patients. The trial met statistical significance, with a hazard ratio of 0.52. Safety data showed manageable side effects. SMMT stock closed at $12.73, up 0.47% in pre-market trading.

rttnews.com2 min
AUG 25
$SMMTMed

Summit Therapeutics Shares Rise After Bernstein SocGen Upgrade

Summit Therapeutics (SMMT) shares rose 1.1% in pre-market trading after Bernstein SocGen upgraded the company to Market Perform from Underperform and raised its price target to $11.90 from $9.80. The broker cited Summit's current valuation as more reflective of ivonescimab's risk-adjusted value, though it remains cautious about the drug's broad market potential. Summit shares have been trading near their 52-week low of $12.07, down 57% from their high of $30.05.

yahoo.com2 min
AUG 25
$SMMTHigh

Why is Summit Therapeutics stock climbing today?

Summit Therapeutics (SMMT) stock rose 1.1% in pre-market trading after Bernstein upgraded it to Market Perform with a $11.90 price target, citing a valuation reset for its drug ivonescimab. The firm assigned a 35% probability of success for the ILLUMINE Phase 3 trial. The stock is near its 52-week low and 57% below its high. The FDA's review of ivonescimab is a long-term catalyst. The broader market is also up, supporting risk assets like biotechs.

investing.com2 min
AUG 22
$SMMTHighAI 8/10

Why Is SMMT Stock Surging Over 10% In Overnight Trading?

Summit Therapeutics (SMMT) shares rose 13% in overnight trading after positive Phase 3 trial data for Ivonescimab in lung cancer. The drug showed improved survival rates over competitors. Pfizer (PFE), Bristol Myers Squibb (BMY), and Merck (MRK) are developing similar therapies. SMMT has an FDA review pending for Ivonescimab in another lung cancer indication.

stocktwits.com2 min
Why is Summit Therapeutics stock surging today? — alphai